SCHEMBL3375937

SCHEMBL3375937

O=S(=O)(O)Nc1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
PTK2B Q14289 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP1A2 P05177 3/20 0.46
CYP2C19 P33261 2/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
GRM4 Q14833 1/20 0.43
POLB P06746 1/20 0.43
CASP6 P55212 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
DHODH Q02127 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6684548 0.84 TSHR (0.42) TSHRMEN1KMT2ASMN1; SMN2
SCHEMBL11417940 0.82 TSHR (0.56) TSHRMEN1KMT2APTK2BKDM4E
SCHEMBL27684159 0.82 MEN1 (0.50) MEN1KMT2AKDM4EHPGDSMN1; SMN2
SCHEMBL11973136 0.80 MAPT (0.53) MEN1KMT2AKDM4ECYP1A2CYP2C19
SCHEMBL2318350 0.78 PTGS1 (0.61) TSHRMEN1KMT2APTK2BKDM4E
SCHEMBL1645161 0.78 TSHR (0.53) TSHRMEN1KMT2APTK2BKDM4E
SCHEMBL27182739 0.77 KMT2A (0.56) TSHRMEN1KMT2APTK2BKDM4E
Sulfuric Acid SCHEMBL8791976 0.77 KDM4E (0.48) TSHRMEN1KMT2APTK2BKDM4E
SCHEMBL1075937 0.76 GAA (0.55) MEN1KMT2AKDM4EHPGDSMN1; SMN2
SCHEMBL7008643 0.76 ALDH1A1 (0.39) MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809267-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2014-08-19 US disclosed
US-20140051626-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 US disclosed
US-8513186-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-08-20 US disclosed
CN-101801925-A antiviral compounds GILEAD SCIENCES INC 2010-08-11 CN disclosed
EP-2162432-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2010-03-17 EP disclosed
WO-2010017405-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2010-02-11 WO disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed
EP-0970148-B1 OLIGOMERIC AZO DYES BASF AG (DE) 2001-06-13 EP disclosed
US-6114512-A REACTING A TETRAZOTIZED DIAMINE COMPOUND WITH A COUPLING COMPOUND CONTAINING AMINONAPHTHOL-MONO OR DI-SULFONIC ACID COMPOUND TO FORM TETRAAZO DYE BASF AKTIENGESELLSCHAFT (DE) 2000-09-05 US disclosed
EP-0970148-A1 OLIGOMERIC AZO DYES BASF AKTIENGESELLSCHAFT (DE) 2000-01-12 EP disclosed
WO-1998041581-A1 OLIGOMERIC AZO DYES BASF AKTIENGESELLSCHAFT (DE) 1998-09-24 WO disclosed
EP-0136142-B1 THERMALLY DEVELOPABLE, LIGHT-SENSITIVE MATERIAL KONICA CORPORATION (JP) 1990-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186869-A1 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 TSHR 4853/4885MEN1 4292/4885KMT2A 3803/4885
US-20140051626-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 TSHR 4853/4885MEN1 4292/4885KMT2A 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.